BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 23.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,535 shares of the company's stock after selling 23,873 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in BioNTech were worth $7,060,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of BNTX. FMR LLC lifted its position in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after purchasing an additional 1,401,547 shares during the period. BNP Paribas Financial Markets bought a new position in BioNTech in the fourth quarter worth approximately $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after buying an additional 433,388 shares during the period. Capital International Investors boosted its position in BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of BioNTech by 3,942.1% in the 4th quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock valued at $15,587,000 after acquiring an additional 133,402 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Up 1.0%

Shares of NASDAQ BNTX traded up $1.04 during mid-day trading on Tuesday, hitting $107.51. The stock had a trading volume of 673,199 shares, compared to its average volume of 940,291. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The company has a 50 day moving average of $102.89 and a two-hundred day moving average of $106.95. BioNTech SE Sponsored ADR has a twelve month low of $76.53 and a twelve month high of $131.49.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of analyst reports. Truist Financial restated a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. The Goldman Sachs Group assumed coverage on shares of BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $137.86.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.